Relationship between plasma concentrations and cardiac beta‐ adrenoceptor blockade‐a study with oral and intravenous bopindolol.
- 1 January 1986
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 21 (1) , 45-51
- https://doi.org/10.1111/j.1365-2125.1986.tb02821.x
Abstract
Bopindolol, an esterified beta‐adrenoceptor blocking drug, was administered to nine healthy male volunteers in oral (1 mg and 4 mg) and intravenous (1 mg) doses. Plasma concentrations determined using a radio‐receptor assay (RRA) and high pressure liquid chromatography (h.p.l.c.) yielded almost identical results, indicating that hydrolysed bopindolol, the major metabolite, is responsible for the pharmacological activity of the drug. After intravenous administration the half‐life for the formation of the hydrolysis product was about 0.3 h. The elimination of hydrolysed bopindolol from the plasma, determined with a one‐compartment model occurred with a half‐life of about 4 h. There were indications for a longer beta phase of elimination with a half‐life of about 8 h, which, owing to the relative insensitivity of the method for concentrations present after more than 24 h, could not be determined exactly. The absolute bioavailability of the active compound is about 70%. Cardiac beta‐adrenoceptor blockade was determined as the reduction in exercise‐induced tachycardia. With oral doses the maximum effect was reached after 3 h (‐29 beats min‐1 after 1 mg, ‐40 beats min‐1 after 4 mg). After intravenous administration most of the effect was present after 0.5 h but the maximum effect (‐33 beats min‐1) was only reached at 3 h. Bopindolol possesses a long duration of action: after 48 h 33% of the maximum effect of the oral dose of 4 mg was still present.(ABSTRACT TRUNCATED AT 250 WORDS)This publication has 13 references indexed in Scilit:
- Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.British Journal of Clinical Pharmacology, 1985
- Simultaneous modeling of bopindolol kinetics and dynamicsClinical Pharmacology & Therapeutics, 1984
- Pindolol‐a beta‐adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.British Journal of Clinical Pharmacology, 1982
- (±)[125Iodo]cyanopindolol, a new ligand for β-adrenoceptors: Identification and quantitation of subclasses of β-adrenoceptors in guinea pigNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1981
- Solubilization of a mammalian ?-adrenergic receptorNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1978
- Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rateClinical Pharmacology & Therapeutics, 1974
- An investigation of the relationship between ?-adrenoceptor blockade and plasma practolol concentration in manEuropean Journal of Clinical Pharmacology, 1974
- Plasma Propranolol Levels in the Quantitative Assessment of -adrenergic Blockade in ManBMJ, 1970